Presently, there are over 20 screening platforms enabling therapy development efforts, By Roots Analysis

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment

 

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-/267.html

• A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration. In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.
• Detailed profiles of large players that are engaged in the development of synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and an excerpt on its developmental history. In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.
• An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.
• An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment. It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).

The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:

• Type of molecule
• Small Molecule
• Biologic

 

• Target disease indication

• Breast Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Gastric Cancer
• Head and Neck Cancer
• Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Others

 

• Type of synlet target

• APE1 / Ref-1
• Chk1
• GLS1
• PARP
• Pol θ
• PP2A
• Wee1

 

• Route of administration 
• Oral
• Intravenous

 

• Key geographical regions
• North America
• Europe
• Asia Pacific

• Rest of the World

 

The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:

• AbbVie
• AstraZeneca
• AtlasMedx
• BeiGene
• Chordia Therapeutics
• Clovis Oncology
• GlaxoSmithKline
• IDEAYA Biosciences
• Mission Therapeutics
• Pfizer
• Repare Therapeutics
• Sierra Oncology
• SyntheX Labs

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction to DNA Damage and Repair Systems
 

4. Introduction to Synthetic Lethality
 

5. Market Overview
 

6. Company Profiles
 

7. Emerging Trends on Social Media
 

8. Publication Analysis
 

9. Abstract Analysis
 

10. Academic Grants Analysis
 

11. Funding and Investment Analysis
 

12. Target Benchmark Analysis

 

13. Role of Companion Diagnostics in Synthetic Lethality

 

14. Market Forecast
 

15. Concluding Remarks
 

16. Executive Insights

 

17. Appendix 1: Tabulated Data

 

18. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]